Cargando…

Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis

BACKGROUND: Shexiang Baoxin pills (SXBXP), as a Traditional Chinese Medicine, are widely used for chronic heart failure in China. It is essential to systematically assess the efficacy and safety of SXBXP as an adjuvant treatment for chronic heart failure. METHODS: Seven English and Chinese electroni...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Taiwei, Wang, Jian, Ma, Xiao, Ma, Rong, Wen, Jianxia, Chen, Nian, Xie, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941719/
https://www.ncbi.nlm.nih.gov/pubmed/29849724
http://dx.doi.org/10.1155/2018/6949348
_version_ 1783321341026369536
author Dong, Taiwei
Wang, Jian
Ma, Xiao
Ma, Rong
Wen, Jianxia
Chen, Nian
Xie, Qian
author_facet Dong, Taiwei
Wang, Jian
Ma, Xiao
Ma, Rong
Wen, Jianxia
Chen, Nian
Xie, Qian
author_sort Dong, Taiwei
collection PubMed
description BACKGROUND: Shexiang Baoxin pills (SXBXP), as a Traditional Chinese Medicine, are widely used for chronic heart failure in China. It is essential to systematically assess the efficacy and safety of SXBXP as an adjuvant treatment for chronic heart failure. METHODS: Seven English and Chinese electronic databases (PubMed, Embase, Cochrane Library, CBM, Wanfang, VMIS, and CNKI) were searched from inception to July 2017. The Cochrane Risk of Bias tool was used to evaluate the methodological quality of eligible studies. Meta-analysis was performed by Review Manager 5.3. RESULTS: A total of 27 RCTs with 2637 participants were included in this review. Compared to conventional treatment, SXBXP combined with conventional treatment showed potent efficacy when it came to the total efficacy rate (OR, 3.88; 95% CI, 2.87, 5.26; P < 0.00001), B-type natriuretic peptide (BNP) (MD = −66.95; 95% CI, −108.57, −25.34; P = 0.002), N-terminal pro-brain natriuretic peptide (NT-ProBNP) (MD = −0.15; 95% CI, −0.21, −0.09; P < 0.00001), six-minute walking distance (6-MWD) (MD = 38.57; 95% CI, 28.47, 48.67; P < 0.00001), cardiac output (CO) (MD = 0.84; 95% CI, 0.68, 0.99; P < 0.00001), and Stroke Volume (SV) (MD = 7.43; 95% CI, 4.42, 10.44, P < 0.00001). The pooled subgroup analysis indicated that there was a significant difference between SXBXP plus conventional treatment and conventional treatment alone in short term course (OR = 3.51; 95% CI, 2.28, 5.40; P < 0.00001), in middle period of treatment (OR = 5.01; 95% CI, 2.61, 9.60; P < 0.00001), and in long-term course (OR = 3.77; 95% CI, 2.13, 6.67; P < 0.00001). No serious adverse events or reactions were mentioned in these RCTs. CONCLUSIONS: As an adjuvant drug, this study suggested that SXBXP provide an obvious efficacy for the treatment of CHF. However, due to small samples and generally low quality studies being applied in this study, more rigorous and well-designed RCTs are needed to confirm these findings.
format Online
Article
Text
id pubmed-5941719
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59417192018-05-30 Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis Dong, Taiwei Wang, Jian Ma, Xiao Ma, Rong Wen, Jianxia Chen, Nian Xie, Qian Evid Based Complement Alternat Med Review Article BACKGROUND: Shexiang Baoxin pills (SXBXP), as a Traditional Chinese Medicine, are widely used for chronic heart failure in China. It is essential to systematically assess the efficacy and safety of SXBXP as an adjuvant treatment for chronic heart failure. METHODS: Seven English and Chinese electronic databases (PubMed, Embase, Cochrane Library, CBM, Wanfang, VMIS, and CNKI) were searched from inception to July 2017. The Cochrane Risk of Bias tool was used to evaluate the methodological quality of eligible studies. Meta-analysis was performed by Review Manager 5.3. RESULTS: A total of 27 RCTs with 2637 participants were included in this review. Compared to conventional treatment, SXBXP combined with conventional treatment showed potent efficacy when it came to the total efficacy rate (OR, 3.88; 95% CI, 2.87, 5.26; P < 0.00001), B-type natriuretic peptide (BNP) (MD = −66.95; 95% CI, −108.57, −25.34; P = 0.002), N-terminal pro-brain natriuretic peptide (NT-ProBNP) (MD = −0.15; 95% CI, −0.21, −0.09; P < 0.00001), six-minute walking distance (6-MWD) (MD = 38.57; 95% CI, 28.47, 48.67; P < 0.00001), cardiac output (CO) (MD = 0.84; 95% CI, 0.68, 0.99; P < 0.00001), and Stroke Volume (SV) (MD = 7.43; 95% CI, 4.42, 10.44, P < 0.00001). The pooled subgroup analysis indicated that there was a significant difference between SXBXP plus conventional treatment and conventional treatment alone in short term course (OR = 3.51; 95% CI, 2.28, 5.40; P < 0.00001), in middle period of treatment (OR = 5.01; 95% CI, 2.61, 9.60; P < 0.00001), and in long-term course (OR = 3.77; 95% CI, 2.13, 6.67; P < 0.00001). No serious adverse events or reactions were mentioned in these RCTs. CONCLUSIONS: As an adjuvant drug, this study suggested that SXBXP provide an obvious efficacy for the treatment of CHF. However, due to small samples and generally low quality studies being applied in this study, more rigorous and well-designed RCTs are needed to confirm these findings. Hindawi 2018-04-24 /pmc/articles/PMC5941719/ /pubmed/29849724 http://dx.doi.org/10.1155/2018/6949348 Text en Copyright © 2018 Taiwei Dong et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Dong, Taiwei
Wang, Jian
Ma, Xiao
Ma, Rong
Wen, Jianxia
Chen, Nian
Xie, Qian
Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis
title Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis
title_full Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis
title_fullStr Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis
title_full_unstemmed Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis
title_short Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis
title_sort shexiang baoxin pills as an adjuvant treatment for chronic heart failure: a system review and meta-analysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941719/
https://www.ncbi.nlm.nih.gov/pubmed/29849724
http://dx.doi.org/10.1155/2018/6949348
work_keys_str_mv AT dongtaiwei shexiangbaoxinpillsasanadjuvanttreatmentforchronicheartfailureasystemreviewandmetaanalysis
AT wangjian shexiangbaoxinpillsasanadjuvanttreatmentforchronicheartfailureasystemreviewandmetaanalysis
AT maxiao shexiangbaoxinpillsasanadjuvanttreatmentforchronicheartfailureasystemreviewandmetaanalysis
AT marong shexiangbaoxinpillsasanadjuvanttreatmentforchronicheartfailureasystemreviewandmetaanalysis
AT wenjianxia shexiangbaoxinpillsasanadjuvanttreatmentforchronicheartfailureasystemreviewandmetaanalysis
AT chennian shexiangbaoxinpillsasanadjuvanttreatmentforchronicheartfailureasystemreviewandmetaanalysis
AT xieqian shexiangbaoxinpillsasanadjuvanttreatmentforchronicheartfailureasystemreviewandmetaanalysis